بدائل البحث:
significant larger » significantly larger (توسيع البحث), significant barrier (توسيع البحث), significant dangers (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
point decrease » point increase (توسيع البحث)
significant larger » significantly larger (توسيع البحث), significant barrier (توسيع البحث), significant dangers (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
point decrease » point increase (توسيع البحث)
-
161
Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
منشور في 2024"…<p>Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…"
-
162
Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
منشور في 2024"…<p>Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…"
-
163
-
164
-
165
-
166
Summary of post-treatment disease course measures from MDMA-AT publications.
منشور في 2025الموضوعات: -
167
-
168
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
169
-
170
-
171
-
172
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
173
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
174
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
175
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
176
-
177
-
178
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: -
179
-
180